Editorial

Publisher Website
Google Scholar
Abstract
Iproniazid in a significant proportion of patients has demonstrated marked effect in relieving the pain in anginal syndrome. Based on the available evidence the drug if used at all in angina pectoris, should be reserved for those patients in which the syndrome has reached the intractable state. There is little evidence that iproniazid influences the primary pathology of the coronary disease process. Considering the possible severe untoward reactions associated with iproniazid therapy, this drug should be used only when the severity of the disease process and the potential value of the agent outweigh the risks associated with this therapy. Severe jaundice and orthostatic hypotension are the most serious complications. Since early 1957 there have been 230 reported cases of clinical jaundice and 51 fatalities. The estimated incidence of the toxic hepatitis is 1 per 4000 patients. The value of this agent as a therapeutic tool in mental depression and related disease states has been amply attested to.

This publication has 0 references indexed in Scilit: